On Tuesday, Tempus AI received a positive adjustment to its Relative Strength (RS) Rating, from 84 to 91.
IBD's unique RS Rating tracks technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
History reveals that the market's biggest winners often have an RS Rating north of 80 at the beginning of a new run.
Here Are 3 Keys For Successful Stock Investing
While the stock is not near an ideal buy zone right now, see if it goes on to form and break out of a proper chart pattern.
The company posted 0% earnings growth last quarter, while sales growth came in at 36%.
Tempus AI holds the No. 9 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Schrodinger are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
